Jayasree and Marijn will present the key findings of the Antimicrobial Resistance Benchmark  with a focus on antibiotic manufacturing and environmental risk-management strategies for slowing AMR. The AMR Benchmark includes detailed analyses of companies’ performances in three areas of corporate activity: R&D for new antimicrobials, policies for ensuring responsible antibiotic manufacturing, and approaches to ensuring antimicrobials are accessible and being used wisely. It aims to guide and incentivise pharmaceutical companies to adopt and implement effective actions for tackling the problem of AMR. The Benchmark has been developed through collaboration with experts and specialists across the spectrum of organisations working to curb AMR.

Related posts